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Lessons learned from SARS-CoV and MERS-CoV:  
FDA-approved Abelson tyrosine-protein kinase 2 
inhibitors may help us combat SARS-CoV-2
Seyed Fazel Nabavi1, Solomon Habtemariam2, Emilio Clementi3,4, Ioana Berindan-Neagoe5,6, 
Cosmin Andrei Cismaru5,7, Mahsa Rasekhian8, Maciej Banach9,10, Morteza Izadi1, Mahdi Bagheri1, 
Mohammad Sadegh Bagheri11, Seyed Mohammad Nabavi1
SARS-CoV-2 is a newly emerging infectious disease, which originated 
from Wuhan in the Hubei province of China in late December 2019 [1]. 
Since then, it has rapidly spread all over the world, and at the time of 
writing this letter, WHO statistics show more than 1,696,588 cases and 
105,952 deaths confirmed across the world [2]. Although there is no 
specific therapy for SARS-CoV-2 infection [3], combination therapy with 
antiviral and anti-inflammatory drugs accompanied by supportive treat-
ment have been used for SARS-CoV-2 patients [4]. The combination of 
well-known HIV protease inhibitors, such as ritonavir with lopinavir, has 
also been a common approach to treat SARS-CoV-2. Insufficient outcome 
in severe cases is, however, one of the main challenges associated with 
the current antiviral-based therapy for SARS-CoV-2 [5]. In view of the 
long period required for novel drug discovery and the desperate need for 
a prompt response to this pandemic infection, one must resort to repur-
posing FDA-approved drugs. In this direction, our experience with other 
close members of coronaviruses such as SARS and MERS has taught us 
that repurposing the current drugs is a reasonable strategy. 
Abelson tyrosine-protein kinase 2 (Abl2), the imatinib target, was re-
quired for efficient SARS-CoV and MERS-CoV replication in vitro [6]. Cole-
man et al. have shown that  the imatinib target Abl2 is indispensable 
for efficient replication of SARS-CoV and MERS-CoV in vitro.
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Abl kinase activity and associated pathways 
have been shown to be involved in the coronavirus 
fusion step with endosomal membrane as well as 
the cell-cell fusion that occurs late in infection [7]. 
The authors have shown that  imatinib  and two 
specific Abl  kinase  inhibitors (GNF2 and GNF5) 
could reduce infectious bronchitis virus (IBV) titres 
by blocking the early entry phase including the 
S-induced syncytia formation prior to the hemifu-
sion step.
Saracatinib, an inhibitor of multiple members 
of the Src family of tyrosine kinases (SFK) (Fyn/
Lyn), together with Abl2 kinase, interferes with 
the early stages of the MERS-CoV life cycle after 
internalisation into Huh-7 cells [8]. Because the 
SFKs regulate multiple  signalling pathways, in-
cluding EGF receptor (EGFR), Ras/Raf/MEK, PI3K/
AKT, and JAK/STAT, the role of Abl kinase inhibition 
by saracatinib in the observed antiviral effect is 
not clear. A plethora of evidences support the idea 
of repurposing kinase inhibitors for inhibition of 
viral replication.
Although there are differences in the transmis-
sion and mortality rates, there are many similarities 
in the genetics, pathogenesis, clinical manifesta-
tion, etc. between SARS-CoV, MERS- Cov, and SARS-
CoV-2 [9]. Previous valuable lessons learned from 
other coronavirus outbreaks and a plethora of re-
search data on this topic can help us select the best 
treatment strategy for managing the 2020 pandem-
ic. Taken together, repurposing the FDA-approved 
Abl2 inhibitors imatinib and saracatinib should be 
clinically tested for their antiviral effects in the ear-
ly stage of SARS-CoV-2 infection, either alone or in 
combination with current antiviral drugs (except ri-
tonavir, due to its interaction with imatinib).
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Figure 1. Abl kinase inhibition of early entry phases in the viral infectious cycle of SARS-CoV2. Upon binding of 
SARS-CoV2 spike protein to ACE2, the action of proteases at the cell membrane and in the endosomal compart-
ment is required to complete the subsequent fusion steps of the virus. Abl kinase inhibitors act on proteases 
required for the completion of these steps by blocking their activity in SARS-CoV and MERS-CoV infection in vitro, 
and a similar activity of proteases is seen in SARS-CoV2
Human cell
Nucleus
Mitochondrion
Golgi
ER
Viral replication 
in ER-derived 
double-membrane 
vesicles under 
the action of 
replicases
Envelope fusion with 
endosomal membrane 
under the action of 
proteases and viral 
nucleocapsid egress 
into the cytoplasm
Viral inter-
nalisation by 
endocytosis 
under the 
action of 
membrane 
proteases and 
ACE2 
binding
Envelope uncoating 
under the action of 
endosomal  
proteases
ACE2
Abl kinase 
inhibitor
Spike protein
Lipid bilayer envelope with 
membrane proteins
RNA
Nucleocapsid
SARS-CoV2
Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2 
Arch Med Sci 3
evidence. Int J Antimicrob Agents 2020; 105948. doi: 
10.1016/j.ijantimicag.2020.105948.
2. World Health Organization. Coronavirus disease 2019 
(COVID-19): situation report, 83. 2020. 
3. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as 
a  potential therapy for COVID-19. Lancet Infect Dis 
2020; 20: 398-400.
4. Stebbing J, Phelan A, Griffin I, et al. COVID-19: combin-
ing antiviral and anti-inflammatory treatments. Lancet 
Infect Dis 2020; 20: 400-2.
5. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritona-
vir in adults hospitalized with severe Covid-19. N Engl 
J Med 2020; doi: 10.1056/NEJMoa2001282.
6. Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, 
Frieman MB. Abelson kinase inhibitors are potent inhib-
itors of severe acute respiratory syndrome coronavirus 
and middle east respiratory syndrome coronavirus fu-
sion. J Virol 2016; 90: 8924-33.
7. Sisk JM, Frieman MB, Machamer CE. Coronavirus S pro-
tein-induced fusion is blocked prior to hemifusion by 
Abl kinase inhibitors. J Gen Virol 2018; 99: 619-30.
8. Shin JS, Jung E, Kim M, Baric RS, Go YY. Saracatinib in-
hibits middle east respiratory syndrome-coronavirus 
replication in vitro. Viruses 2018; 10: 283.
9. Katsiki N, Banach M, Mikhailidis DP. Lipid lowering ther-
apy and renin-angiotensin-aldosterone system inhibi-
tors in the era of the COVID-19 pandemic. Arch Med Sci 
2020; 16(3); doi: https://doi.org/10.5114/aoms.2020. 
94503.
